[
  {
    "id": 181,
    "question": "What to expect from O.A. infarction",
    "option_a": "Ipsilateral Horner",
    "option_b": "Ipsilateral hearing loss",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nOphthalmic artery (OA) infarction is an ocular ischemic event resulting from an abrupt interruption of blood flow to the retina. This condition is most commonly associated with embolic or thrombotic occlusion of the ophthalmic artery, a branch of the internal carotid artery.\n\n**Pathophysiology**\n\nWhen the ophthalmic artery is occluded, the retina suffers an abrupt ischemic insult because it has minimal collateral supply. The resulting retinal ischemia quickly leads to cell death and irreversible vision loss unless very prompt interventions are instituted. The embolus may originate from atherosclerotic plaques or cardioembolic sources.\n\n**Clinical Correlation**\n\nClinically, OA infarction presents as sudden, usually painless, monocular visual loss. Patients may also exhibit a relative afferent pupillary defect on examination with fundoscopic findings such as a pale retina with a cherry-red spot at the fovea. In contrast, signs such as ipsilateral Horner syndrome or hearing loss are more typical with other vascular territories (e.g., carotid dissection or labyrinthine infarction).\n\n**Diagnostic Approach**\n\nDiagnosis is made with an urgent ophthalmologic evaluation including fundoscopic exam and ancillary tests such as fluorescein angiography. Vascular imaging (e.g., carotid Doppler ultrasound or CTA) should be pursued to identify embolic sources. Differential diagnoses include central retinal artery occlusion (CRAO) from other causes, giant cell arteritis (in older individuals), and acute optic neuritis.\n\n**Management Principles**\n\nManagement is considered emergent. Options include measures aimed at dislodging the embolus (e.g., ocular massage, intraocular pressure reduction with medications) and systemic management (antiplatelet agents, risk factor optimization). There is limited evidence for thrombolytic or surgical interventions in this setting. In pregnant or lactating patients, any systemic medications must be carefully chosen to balance maternal benefit with fetal/neonatal safety; procedural interventions, when deemed life- or sight\u2010saving, are generally pursued with appropriate shielding and precautions.\n\n**Option Analysis**\n\n\u2022 Option A (Ipsilateral Horner): This finding is more characteristic of carotid dissection rather than an OA infarction. \n\u2022 Option B (Ipsilateral Hearing Loss): Sudden hearing loss is more typically seen with infarction of the labyrinthine artery (usually a branch of the anterior inferior cerebellar artery) rather than the ophthalmic artery. \n\u2022 Option C: Although the text is missing here, it is presumed that Option C was intended to describe the hallmark presentation of OA infarction (i.e., acute, painless monocular vision loss with retinal findings). \n\u2022 Option D: Not provided.\n\n**Clinical Pearls**\n\n1. The retina is exquisitely sensitive to ischemia, and irreversible damage may occur within a short time window. \n2. Sudden monocular vision loss should prompt immediate evaluation for vascular occlusive disease. \n3. Always consider systemic vascular risk factors and embolic sources in patients with ocular ischemia.\n\n**Current Evidence**\n\nRecent studies and reviews have emphasized that early recognition and treatment of retinal arterial occlusions are crucial; however, no treatment modality (including thrombolysis) has consistently proven effective. Current guidelines remain focused on rapid risk factor assessment and secondary prevention rather than a standardized acute intervention, and research into hyperacute reperfusion strategies is ongoing.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "id": 182,
    "question": "45 YO female came with SAH and found to have P-chom aneurysm what's next",
    "option_a": "Endovascular coiling",
    "option_b": "Surgical clipping",
    "option_c": "Observation",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nAneurysmal subarachnoid hemorrhage (SAH) with a posterior communicating (P-com or P-chom) artery aneurysm is a neurosurgical emergency. The primary goal is to prevent rebleeding by securing the aneurysm.\n\n**Pathophysiology**\n\nRupture of a P-com aneurysm leads to bleeding into the subarachnoid space, causing a sudden rise in intracranial pressure, meningeal irritation, and potential for vasospasm. The P-com aneurysm is one of the common sites for aneurysms and is intimate with the oculomotor nerve, which can lead to nerve palsies.\n\n**Clinical Correlation**\n\nPatients typically present with a sudden, severe (\u2018thunderclap\u2019) headache, often accompanied by neck stiffness, nausea/vomiting, and in some cases, focal neurological deficits such as third nerve palsy. Rapid identification and treatment are essential to reduce mortality and complications from rebleeding or vasospasm.\n\n**Diagnostic Approach**\n\nInitial evaluation includes a non\u2010contrast CT scan to detect SAH, followed by vascular imaging such as CT angiography (CTA) or digital subtraction angiography (DSA) to diagnose and precisely localize the aneurysm. Differential diagnoses include other causes of SAH such as perimesencephalic hemorrhage and arteriovenous malformations.\n\n**Management Principles**\n\nThe definitive management is to secure the aneurysm. Endovascular coiling is generally considered the first-line intervention when the aneurysm anatomy is favorable, particularly following large randomized trials (such as the ISAT) which demonstrated improved outcomes with coiling in appropriate cases. Surgical clipping remains an alternative when coiling is not feasible. In pregnant or lactating patients, the decision must balance maternal risk and fetal exposure to radiation and contrast agents; shielding and careful procedural planning can mitigate risks.\n\n**Option Analysis**\n\n\u2022 Option A (Endovascular coiling): Correct \u2013 It is considered first-line therapy for many ruptured aneurysms, including P-com aneurysms, when anatomy permits. \n\u2022 Option B (Surgical clipping): While a valid alternative, it is typically reserved for aneurysms not amenable to endovascular treatment. \n\u2022 Option C (Observation): Inappropriate in the context of a ruptured aneurysm due to the imminent risk of rebleeding.\n\n**Clinical Pearls**\n\n1. In aneurysmal SAH, securing the aneurysm as early as possible greatly reduces the risk of rebleeding. \n2. P-com aneurysms can produce an acute third nerve palsy. \n3. The ISAT trial has significantly influenced the preference for endovascular management in suitable aneurysms.\n\n**Current Evidence**\n\nCurrent guidelines and recent evidence support endovascular coiling as a first\u2010line therapy for ruptured cerebral aneurysms when indicated by their size and shape. Ongoing research continues to refine criteria for selecting between clipping and coiling, with an emphasis on reducing complications and improving long-term outcomes.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "id": 183,
    "question": "Clear scenario of anterior choroidal artery infarction, they brought VF suggestive of it",
    "option_a": "anterior choroidal artery infarction",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nAnterior choroidal artery infarction is a distinct type of ischemic stroke affecting the small branch of the internal carotid system. It has a characteristic clinical presentation that helps localize the lesion.\n\n**Pathophysiology**\n\nOcclusion of the anterior choroidal artery results in ischemia of structures such as the posterior limb of the internal capsule, parts of the optic radiation, and the medial temporal lobe. The resulting infarct produces a combination of motor, sensory, and visual deficits.\n\n**Clinical Correlation**\n\nPatients with anterior choroidal artery infarction may show contralateral hemiparesis, hemisensory loss, and specific visual field deficits (typically a homonymous hemianopia). The presence of a visual field defect that corresponds with the infarct territory supports the diagnosis.\n\n**Diagnostic Approach**\n\nDiagnosis is made via neuroimaging studies \u2013 diffusion-weighted MRI is highly sensitive in the hyperacute setting, while CT scans can help in the early phase and rule out hemorrhage. Differential diagnoses include lacunar strokes from other small vessel occlusions and infarctions in the posterior cerebral artery territory.\n\n**Management Principles**\n\nManagement of an anterior choroidal artery infarct follows standard acute ischemic stroke protocols. If the patient presents within the thrombolytic window, IV thrombolysis may be indicated. Secondary prevention with antiplatelet agents, control of risk factors (hypertension, diabetes, hyperlipidemia), and rehabilitation are essential. In pregnant or lactating patients, thrombolytic use is carefully considered based on risk-benefit analysis, and antiplatelet therapy selection is guided by safety data in these populations.\n\n**Option Analysis**\n\n\u2022 Option A (Anterior choroidal artery infarction): Correct \u2013 the clinical vignette clearly supports this diagnosis. \n\u2022 Other options: Not provided, making Option A the only and thus the correct answer in context.\n\n**Clinical Pearls**\n\n1. The classic triad of anterior choroidal artery infarction is contralateral hemiparesis, hemisensory loss, and homonymous hemianopia. \n2. Diffusion-weighted MRI is the gold standard for early detection of small vessel strokes. \n3. Prompt recognition allows for timely intervention and secondary prevention.\n\n**Current Evidence**\n\nRecent studies reiterate the importance of early imaging and intervention in ischemic stroke. Guidelines continue to support thrombolysis for eligible patients with small vessel infarcts, and ongoing research focuses on neuroprotective strategies and long-term rehabilitation outcomes.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "id": 184,
    "question": "Stroke all stroke workups mentioned except CTA asked what to do next",
    "option_a": "(CTA): Correct",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nAcute stroke workup aims not only to rule out hemorrhage but also to evaluate the cerebral vasculature for occlusions or stenoses that may guide reperfusion strategies like thrombectomy. CTA (computed tomography angiography) is critical for visualizing the intracranial vessels.\n\n**Pathophysiology**\n\nIn the setting of an ischemic stroke, rapid imaging beyond a non-contrast CT is essential to assess vessel patency. CTA provides detailed images of both extracranial and intracranial arteries, identifying occlusions or significant stenoses that could be amenable to endovascular intervention.\n\n**Clinical Correlation**\n\nAfter initial stroke imaging (typically non-contrast CT to exclude hemorrhage), if the clinical picture supports an ischemic stroke and intervention is under consideration, CTA is the next step. It is especially indicated in patients who may benefit from mechanical thrombectomy and helps in differentiating large vessel occlusion strokes from smaller infarcts.\n\n**Diagnostic Approach**\n\nThe standard acute stroke imaging protocol begins with a non-contrast head CT followed by CTA to assess the cerebral vasculature. Differential imaging modalities such as MRA or carotid Doppler have more limited roles in the hyperacute phase. Carotid Doppler, for instance, evaluates mainly extracranial vessels, while MRI/MRA may not be rapidly available.\n\n**Management Principles**\n\nOnce CTA confirms large vessel occlusion or other vascular abnormalities, the treatment plan may include intravenous thrombolysis (if within the time window) followed by mechanical thrombectomy. In pregnancy or lactating patients, careful shielding is employed to reduce fetal radiation exposure; decisions are based on a risk-benefit assessment given the emergent nature of stroke.\n\n**Option Analysis**\n\n\u2022 Option A (CTA): Correct \u2013 It is the next appropriate step as it provides essential vascular information that complements non-contrast CT findings. \n\u2022 Other options (Non-contrast CT alone, carotid Doppler, MRI/MRA, cardiac evaluation): These are either limited in vascular evaluation or not immediately practical in the emergent setting and therefore do not replace CTA in acute stroke protocols.\n\n**Clinical Pearls**\n\n1. CTA is indispensable in the acute stroke setting for identifying large vessel occlusions that might benefit from thrombectomy. \n2. Time is brain: rapid and accurate imaging directly influences acute management and outcomes. \n3. Integration of CTA findings with clinical assessment optimizes patient selection for reperfusion therapies.\n\n**Current Evidence**\n\nRecent guidelines from the American Heart Association/American Stroke Association (AHA/ASA) underscore the importance of CTA in acute stroke protocols. Research continues to refine imaging selection criteria to identify patients most likely to benefit from advanced endovascular therapies.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "id": 185,
    "question": "Scenario patient feeling unwell, then start seeing animals after which he had decreased LOC intubated, decerebrate posturing CT brain attached showed hyperdense basilar sign otherwise no clear ischemic changes what to do next",
    "option_a": "(CTA) is correct because after seeing the hyperdense basilar sign, CTA is the appropriate next diagnostic step to determine the exact location and extent of the occlusion. Option B (EEG) is incorrect because EEG evaluates electrical brain activity and is not useful in diagnosing vascular occlusions.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nThe hyperdense basilar artery sign is a classic radiologic clue for basilar artery occlusion. In a patient with altered mental status and brainstem signs (e.g., decerebrate posturing), identifying a vascular occlusion is critical. CTA is recognized as the primary non\u2010invasive vascular imaging modality to evaluate suspected occlusions.\n\n**Pathophysiology**\n\nBasilar artery occlusion is generally the result of thromboembolic disease. The hyperdense sign on noncontrast CT represents a clot within the artery, which leads to reduced or absent blood flow to brainstem structures. This occlusion results in ischemia of critical structures, leading to rapid neurologic deterioration, as evidenced by decreased level of consciousness and posturing abnormalities.\n\n**Clinical Correlation**\n\nClinically, patients with basilar artery occlusion may present with symptoms ranging from visual disturbances and vertigo to coma and decerebrate posturing because of brainstem involvement. The acute neurologic deterioration observed in this case fits the profile of a posterior circulation stroke.\n\n**Diagnostic Approach**\n\nAfter identifying the hyperdense sign on CT, the next step is to perform computed tomography angiography (CTA) to confirm the diagnosis. Differential diagnoses may include other causes of coma or brainstem dysfunction such as hemorrhage, encephalitis, or metabolic derangements; however, the imaging clue of a hyperdense artery specifically points to vascular occlusion.\n\n**Management Principles**\n\nOnce a basilar artery occlusion is confirmed on CTA, management may include intravenous thrombolysis if within the time window and mechanical thrombectomy. Early recanalization is critical for reducing morbidity and mortality. In pregnant or lactating patients, the use of CTA is generally considered safe with appropriate shielding, and treatment decisions (such as IV thrombolysis) require a careful risk-benefit analysis balancing maternal and fetal risks.\n\n**Option Analysis**\n\nOption A (CTA) is correct because after seeing the hyperdense basilar sign, CTA is the appropriate next diagnostic step to determine the exact location and extent of the occlusion. Option B (EEG) is incorrect because EEG evaluates electrical brain activity and is not useful in diagnosing vascular occlusions.\n\n**Clinical Pearls**\n\n1. The hyperdense basilar artery sign on noncontrast CT is an important early indicator of basilar occlusion. 2. CTA is the gold standard noninvasive imaging modality for confirming vascular occlusions in acute stroke settings.\n\n**Current Evidence**\n\nRecent stroke management guidelines emphasize the importance of rapid vascular imaging in suspected posterior circulation strokes. Studies have confirmed that early CTA allows for prompt decision-making regarding reperfusion therapies, which is critical in basilar occlusion cases.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "id": 186,
    "question": "Rt small thalamic hemorrhage since one day, BP normal, pic attached no hydro or ventricular extension what to do next",
    "option_a": "(Prophylactic LMWH) is correct and is supported by current guidelines for preventing thromboembolic complications in patients with stable intracerebral hemorrhage. Option B (EVD) is incorrect because external ventricular drainage is reserved for cases with significant hydrocephalus or intraventricular hemorrhage, which is not present in this case.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nIn patients with a small thalamic hemorrhage, after 24 hours if the hemorrhage remains stable and there is no evidence of hydrocephalus or intraventricular extension, the major concern becomes the prevention of venous thromboembolism (VTE). Prophylactic low molecular weight heparin (LMWH) is commonly used in this scenario.\n\n**Pathophysiology**\n\nSmall deep hemorrhages, such as those occurring in the thalamus, if not complicated by expansion or ventricular involvement, primarily pose a risk for secondary complications like deep vein thrombosis (DVT) due to immobility. The prophylactic use of LMWH helps mitigate this risk while the hemorrhage is stable.\n\n**Clinical Correlation**\n\nThe patient has a right thalamic hemorrhage that appears stable without hydrocephalus or ventricular extension on imaging. The stable nature of the hemorrhage makes it safe to initiate VTE prophylaxis, as the risk of bleeding expansion is minimized after the first 24 hours.\n\n**Diagnostic Approach**\n\nDifferential considerations include hemorrhagic transformation of an ischemic stroke, hypertensive hemorrhage, and vascular malformations. However, in the absence of hydrocephalus or ventricular extension, conservative management with VTE prophylaxis is most appropriate. Serial imaging may be done to monitor hematoma stability.\n\n**Management Principles**\n\nAfter 24 hours of hemorrhage stability, initiating prophylactic LMWH for DVT prevention is recommended in current stroke guidelines. Blood pressure management and neurological monitoring remain essential. In pregnant patients, LMWH is favored over unfractionated heparin for VTE prophylaxis due to its better safety profile, and it is generally considered safe in lactation.\n\n**Option Analysis**\n\nOption A (Prophylactic LMWH) is correct and is supported by current guidelines for preventing thromboembolic complications in patients with stable intracerebral hemorrhage. Option B (EVD) is incorrect because external ventricular drainage is reserved for cases with significant hydrocephalus or intraventricular hemorrhage, which is not present in this case.\n\n**Clinical Pearls**\n\n1. Prophylactic LMWH is indicated for DVT prevention in patients with stable small ICH after 24 hours. 2. EVD is not indicated unless there are signs of obstructive hydrocephalus or significant ventricular involvement.\n\n**Current Evidence**\n\nRecent clinical trials and guidelines (such as those from the American Heart Association) support the early initiation of prophylactic anticoagulation with LMWH for patients with small, stable intracerebral hemorrhages, while carefully monitoring for any signs of hematoma expansion.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "id": 187,
    "question": "Male with progressive myelopathy attached image clearly showing slow void, and long cord signal changes, dx",
    "option_a": "(DAVF) is correct because the clinical presentation of a progressive myelopathy combined with the specific MRI findings (slow flow voids and long cord signal abnormalities) strongly supports a diagnosis of spinal dural arteriovenous fistula. Other options such as multiple sclerosis, transverse myelitis, or neoplasm lack the combination of flow voids and progressive cord changes seen in DAVF.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nSpinal dural arteriovenous fistula (DAVF) is a vascular malformation where an abnormal connection exists between a dural artery and a draining vein. It typically presents with progressive myelopathy and distinct MRI findings, including long segment T2 hyperintensity within the cord and flow voids representing abnormal vessels.\n\n**Pathophysiology**\n\nIn DAVF, the arterial blood shunts directly into the venous system, leading to increased venous pressure and congestion. This venous hypertension results in chronic spinal cord ischemia and demyelination, manifesting as progressive neurological deficits over time.\n\n**Clinical Correlation**\n\nPatients, often middle-aged males, present with progressive myelopathy characterized by symptoms such as gait disturbances and lower extremity weakness. The presence of flow voids (indicative of abnormal, dilated vessels) and longitudinal cord signal changes on MRI strongly point towards DAVF rather than inflammatory, demyelinating, or neoplastic processes.\n\n**Diagnostic Approach**\n\nThe differential diagnosis includes multiple sclerosis, transverse myelitis, spinal cord neoplasms, and infectious myelitis. Unlike these conditions, DAVF is suggested by the presence of flow voids on MRI and a gradual progression of myelopathy. Definitive diagnosis is usually confirmed with digital subtraction angiography (DSA), which maps the vascular anatomy in detail.\n\n**Management Principles**\n\nThe first-line management for DAVF is endovascular embolization, which aims at occluding the fistula. Open surgical ligation is considered when embolization is not feasible or if the fistula recurs. In pregnant patients, the timing and modality of intervention require a careful multidisciplinary approach to balance maternal neurological recovery with fetal safety; similarly, lactating patients may need tailored anesthesia and procedural planning.\n\n**Option Analysis**\n\nOption A (DAVF) is correct because the clinical presentation of a progressive myelopathy combined with the specific MRI findings (slow flow voids and long cord signal abnormalities) strongly supports a diagnosis of spinal dural arteriovenous fistula. Other options such as multiple sclerosis, transverse myelitis, or neoplasm lack the combination of flow voids and progressive cord changes seen in DAVF.\n\n**Clinical Pearls**\n\n1. Flow voids on spinal MRI are a key indicator of abnormal vascular channels typical of DAVF. 2. Early diagnosis and treatment are essential to prevent permanent neurological deficits.\n\n**Current Evidence**\n\nCurrent literature and updated neurovascular guidelines advocate for prompt diagnosis and early endovascular treatment of spinal DAVF to halt progression of myelopathy, with emerging evidence supporting the efficacy and safety of these interventions.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "id": 188,
    "question": "Male with renal impairment, stroke, angiokeratoma pic asking about enzyme supp",
    "option_a": ", which corresponds to enzyme replacement with alpha",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nFabry disease is an X-linked lysosomal storage disorder caused by a deficiency of the enzyme alpha-galactosidase A. This deficiency leads to systemic accumulation of glycosphingolipids, particularly globotriaosylceramide, affecting various organs including the kidneys, heart, nervous system, and skin.\n\n**Pathophysiology**\n\nThe lack of sufficient alpha-galactosidase A results in progressive deposition of glycosphingolipids within vascular endothelial cells and other tissues. The accumulation in blood vessels contributes to ischemic events such as stroke, while deposition in the skin leads to angiokeratoma formation. Renal impairment is also a common complication due to the buildup in the kidneys.\n\n**Clinical Correlation**\n\nThe classic clinical triad of Fabry disease includes stroke (especially in younger males), renal dysfunction, and characteristic angiokeratomas. The presence of angiokeratomas, along with a history of renal impairment and stroke, strongly points toward Fabry disease as the underlying diagnosis.\n\n**Diagnostic Approach**\n\nDiagnosis is typically confirmed by measuring alpha-galactosidase A enzyme activity in plasma or leukocytes, along with genetic testing for mutations in the GLA gene. Differential diagnoses include other lysosomal storage disorders such as Gaucher, Pompe, and Krabbe diseases which have distinct enzyme deficiencies and clinical presentations.\n\n**Management Principles**\n\nThe mainstay of Fabry disease treatment is enzyme replacement therapy (ERT) with recombinant alpha-galactosidase A. Early initiation of ERT can reduce glycosphingolipid deposition and ameliorate clinical symptoms. In pregnant women, the decision to initiate or continue ERT should involve a multidisciplinary team with careful risk-benefit analysis, as data are limited but suggest that treatment may be continued if clearly beneficial. Lactating patients should also receive tailored counseling regarding the safety profile of ERT during breastfeeding.\n\n**Option Analysis**\n\nOption A, which corresponds to enzyme replacement with alpha-galactosidase A (often noted as 'Galtcosidase'), is correct because this directly addresses the underlying deficiency in Fabry disease. Other enzymes mentioned (e.g., beta-glucocerebrosidase, alpha-glucosidase, or galactocerebrosidase) are associated with different lysosomal storage disorders and are therefore incorrect in this context.\n\n**Clinical Pearls**\n\n1. Always consider Fabry disease in younger patients presenting with stroke, renal impairment, and characteristic skin lesions (angiokeratomas). 2. Enzyme replacement therapy with recombinant alpha-galactosidase A is the current disease-specific treatment for Fabry disease.\n\n**Current Evidence**\n\nRecent clinical studies and guideline updates continue to support the early use of ERT in Fabry disease to slow disease progression and improve outcomes. Ongoing research is looking into adjunctive therapies and optimal timing for initiating treatment, especially in special populations such as pregnant or lactating women.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "id": 189,
    "question": "14 years old boy with intense lancinating pain in feet. His 16 years old sister has same but milder symptoms. There is positive history of strokes in his maternal grandfather before age of 50. On examination; \u2193 pain sensation distally. His lower trunk evident for abnormal skin lesions as attached. What is the best test to reach diagnosis?",
    "option_a": "\u03b1-Galactosidase activity",
    "option_b": "Transferritine",
    "option_c": "VLCFA",
    "option_d": "PME22 gene",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nFabry disease is an X\u2010linked lysosomal storage disorder caused by deficient activity of the enzyme \u03b1\u2010galactosidase A. This enzyme deficiency leads to the accumulation of glycosphingolipids, particularly globotriaosylceramide, in various tissues including blood vessel walls, nerves, and skin.\n\n**Pathophysiology**\n\nDue to a mutation in the GLA gene, the decreased activity of \u03b1\u2010galactosidase A results in the progressive deposition of globotriaosylceramide in endothelial cells, nerve cells, and other tissues. This accumulation causes vascular dysfunction, ischemia, and neuropathic pain. It also leads to characteristic skin lesions (angiokeratomas) and can predispose patients to early strokes.\n\n**Clinical Correlation**\n\nThe 14\u2010year\u2010old boy presenting with intense, lancinating pain in the feet and decreased pain sensation, alongside his sister\u2019s milder symptoms and a maternal grandfather with premature stroke, is highly suggestive of Fabry disease. The presence of skin lesions further strengthens the diagnosis since angiokeratomas are a hallmark of the condition.\n\n**Diagnostic Approach**\n\nThe diagnostic workup involves measuring \u03b1\u2010galactosidase A activity in plasma or leukocytes. Differential diagnoses to consider include other neuropathies such as diabetic neuropathy or hereditary sensory neuropathies; however, the combination of neuropathic pain, characteristic angiokeratomas, and a family history of early cerebrovascular events is specific for Fabry disease.\n\n**Management Principles**\n\nManagement initially involves enzyme replacement therapy (ERT) with agents such as agalsidase beta or agalsidase alfa to reduce substrate accumulation. For symptomatic relief, pain management strategies are employed. In addition, regular monitoring for renal, cardiac, and cerebrovascular complications is necessary. In pregnant or lactating women, the decision to initiate ERT must balance maternal benefits against potential risks, with recent guidelines generally supporting its use when indicated.\n\n**Option Analysis**\n\nOption A (\u03b1\u2010Galactosidase activity) is the correct test for diagnosing Fabry disease. Option B (Transferritine) is related to iron metabolism and not relevant here. Option C (VLCFA) is used in the diagnostic workup of peroxisomal disorders like adrenoleukodystrophy. Option D (PME22 gene) pertains to certain hereditary neuropathies and is not applicable in this scenario.\n\n**Clinical Pearls**\n\n1. Fabry disease should be considered in young patients with neuropathic pain and characteristic skin lesions. 2. An X\u2010linked inheritance pattern can lead to variable expression in females. 3. Early enzyme replacement can help mitigate long\u2010term complications such as renal and cerebrovascular disease.\n\n**Current Evidence**\n\nRecent research supports the use of both enzyme replacement therapy and, in certain cases, chaperone therapy (e.g., migalastat) in patients with amenable mutations. Current guidelines stress early diagnosis and intervention to manage systemic complications efficiently.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "id": 190,
    "question": "Scenario typical for homocystinemia; thin tall patient with lens dislocation, slowly progressive cognitive delay. What is the best supplement to risk of further neurological symptoms and stroke?",
    "option_a": "Vitamin B6",
    "option_b": "Folate",
    "option_c": "Cobalamine",
    "option_d": "Something unrelated",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "**Conceptual Foundation**\n\nFabry disease is an X\u2010linked lysosomal storage disorder caused by deficient activity of the enzyme \u03b1\u2010galactosidase A. This enzyme deficiency leads to the accumulation of glycosphingolipids, particularly globotriaosylceramide, in various tissues including blood vessel walls, nerves, and skin.\n\n**Pathophysiology**\n\nDue to a mutation in the GLA gene, the decreased activity of \u03b1\u2010galactosidase A results in the progressive deposition of globotriaosylceramide in endothelial cells, nerve cells, and other tissues. This accumulation causes vascular dysfunction, ischemia, and neuropathic pain. It also leads to characteristic skin lesions (angiokeratomas) and can predispose patients to early strokes.\n\n**Clinical Correlation**\n\nThe 14\u2010year\u2010old boy presenting with intense, lancinating pain in the feet and decreased pain sensation, alongside his sister\u2019s milder symptoms and a maternal grandfather with premature stroke, is highly suggestive of Fabry disease. The presence of skin lesions further strengthens the diagnosis since angiokeratomas are a hallmark of the condition.\n\n**Diagnostic Approach**\n\nThe diagnostic workup involves measuring \u03b1\u2010galactosidase A activity in plasma or leukocytes. Differential diagnoses to consider include other neuropathies such as diabetic neuropathy or hereditary sensory neuropathies; however, the combination of neuropathic pain, characteristic angiokeratomas, and a family history of early cerebrovascular events is specific for Fabry disease.\n\n**Management Principles**\n\nManagement initially involves enzyme replacement therapy (ERT) with agents such as agalsidase beta or agalsidase alfa to reduce substrate accumulation. For symptomatic relief, pain management strategies are employed. In addition, regular monitoring for renal, cardiac, and cerebrovascular complications is necessary. In pregnant or lactating women, the decision to initiate ERT must balance maternal benefits against potential risks, with recent guidelines generally supporting its use when indicated.\n\n**Option Analysis**\n\nOption A (\u03b1\u2010Galactosidase activity) is the correct test for diagnosing Fabry disease. Option B (Transferritine) is related to iron metabolism and not relevant here. Option C (VLCFA) is used in the diagnostic workup of peroxisomal disorders like adrenoleukodystrophy. Option D (PME22 gene) pertains to certain hereditary neuropathies and is not applicable in this scenario.\n\n**Clinical Pearls**\n\n1. Fabry disease should be considered in young patients with neuropathic pain and characteristic skin lesions. 2. An X\u2010linked inheritance pattern can lead to variable expression in females. 3. Early enzyme replacement can help mitigate long\u2010term complications such as renal and cerebrovascular disease.\n\n**Current Evidence**\n\nRecent research supports the use of both enzyme replacement therapy and, in certain cases, chaperone therapy (e.g., migalastat) in patients with amenable mutations. Current guidelines stress early diagnosis and intervention to manage systemic complications efficiently.",
    "exam_year": "2022",
    "exam_type": "Part I"
  }
]